These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27922588)

  • 41. Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in Taiwan.
    Lin CF; Gau CS; Wu FL; Hsiao FY; Bai CH; Shen LJ
    Clin Ther; 2011 Sep; 33(9):1120-31. PubMed ID: 21872930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Statin intolerance].
    Graversen CB; Larsen ML; Schmidt EB
    Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Statins in practice of the vascular surgeon and cardiologist].
    Pokrovskiĭ AV; Suntsov DS
    Angiol Sosud Khir; 2009; 15(2):123-7. PubMed ID: 19806952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Lowering cholesterol: how low is low enough?].
    Czuriga I; Edes I
    Orv Hetil; 2006 Jul; 147(29):1349-56. PubMed ID: 16941825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape.
    Pedicino D; Volpe M
    Eur Heart J; 2022 Nov; 43(41):4227-4228. PubMed ID: 36101476
    [No Abstract]   [Full Text] [Related]  

  • 47. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
    Robinson JG; Davidson MH
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):461-76. PubMed ID: 16918265
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update on statins and other lipid-lowering drugs.
    Miller CA
    Geriatr Nurs; 2001; 22(5):276-7. PubMed ID: 11606910
    [No Abstract]   [Full Text] [Related]  

  • 49. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The ezetimibe controversy: implications for clinical practice.
    Khanderia U; Regal RE; Rubenfire M; Boyden T
    Ther Adv Cardiovasc Dis; 2011 Aug; 5(4):199-208. PubMed ID: 21636623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
    Reddy V; Allison J; Mounsey A
    J Fam Pract; 2023 Jun; 72(5):227-229. PubMed ID: 37339492
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
    Krempf M; Simpson RJ; Ramey DR; Brudi P; Giezek H; Tomassini JE; Lee R; Farnier M
    Lipids Health Dis; 2015 May; 14():45. PubMed ID: 25985907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An investigative look: selective cholesterol absorption inhibitors--embarking on a new standard of care.
    Stein EA
    Am J Manag Care; 2002 Feb; 8(2 Suppl):S36-9; discussion S45-7. PubMed ID: 11855701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Combined Lipid-Lowering Therapy in Elderly and Senile Patients].
    Shaposhnik II; Genkel VV; Salashenko AO
    Kardiologiia; 2020 Aug; 60(7):103-107. PubMed ID: 33155948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Statins and the cholesterol mortality paradox.
    Nunes JP
    Scott Med J; 2017 Feb; 62(1):19-23. PubMed ID: 27889702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Low persistence of simvastatin and ezetimibe fixed combination in the lipid lowering therapy].
    Simonyi G; Ferenci T
    Orv Hetil; 2015 Jan; 156(4):141-5. PubMed ID: 25597318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels.
    Moutzouri E; Liberopoulos EN; Florentin M; Liamis G; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):13-8. PubMed ID: 22539817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus.
    Miao XY; Liu HZ; Jin MM; Sun BR; Tian H; Li J; Li N; Yan ST
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2302-2310. PubMed ID: 30915779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.